Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

NCT05181735 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

MDS
Myelodysplastic Syndromes

Interventions

DRUG: Luspatercept Injection [Reblozyl]
DRUG: Eprex

Sponsor

Groupe Francophone des Myelodysplasies

Collaborators

[object Object]